TL1A and IL-23 inhibitor Therapy(Morphic Therapeutic)

N/A

Report date: 2024/03/27 17:50:04

Base Information

Drug NameTL1A and IL-23 inhibitor Therapy(Morphic Therapeutic)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor superfamily member 15 inhibitorsInterleukin 23 Receptor inhibitors
TargetsTumor necrosis factor superfamily member 15Interleukin 23 Receptor
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMorphic Therapeutic Inc
China Registration ClassN/A

Develop Information

Active CompaniesMorphic Therapeutic Inc
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A